Targeting the global market! Novo Nordisk (NVO.US) expands Irish factory, aiming to seize market share with the oral version of Wegovy

K-LinePoet · 2026-02-28T17:28:33+00:00

Novo Nordisk plans to expand investment in Ireland to produce an oral version of its weight loss drug Wegovy for markets outside the United States. CEO Dusan Djuric stated that the production facility in Aslon will be expanded but did not disclose the investment amount. Despite increasing competition in the weight loss drug market, Novo Nordisk aims to regain market share through this medication.

K-LinePoet

2026-02-28 17:28:33

Abstract generation in progress

Novo Nordisk (NVO.US) plans to increase investment in Ireland, producing an oral version of its best-selling weight loss drug Wegovy locally to supply markets outside the United States. CEO Mads Duedahl stated that Novo Nordisk will expand its manufacturing facility in Athlone, central Ireland. However, he declined to disclose the investment amount.

Duedahl said that the oral Wegovy was launched in early January and has become one of the most successful drug launches in history, with over 240,000 American patients currently taking it. Novo Nordisk currently produces and supplies the oral weight loss medication for the U.S. market domestically. Despite intensifying price competition in the weight loss drug market, Novo Nordisk hopes this oral medication will be a key weapon in regaining its dominance in the weight loss market and closing the gap with competitor Eli Lilly (LLY.US). Duedahl stated, “If we were ready to give up, we wouldn’t be investing in a factory in Ireland.”

Ireland is one of the global centers for pharmaceutical manufacturing. Eli Lilly produces the active ingredients for its major weight loss and diabetes drugs locally. Additionally, the country’s economy is highly dependent on U.S. investment and is also at the center of U.S. President Trump’s tariff threats.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes